SCYNEXIS, Inc.

SCYNEXIS, Inc.

Novel Anti-Infective Treatments

We are pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. Our lead candidate, ibrexafungerp (formerly known as SCY-078), is a broad-spectrum, IV/oral antifungal agent representing a novel therapeutic class, currently under regulatory review for the treatment of vaginal yeast infection, also known as vulvovaginal candidiasis (VVC), and in late stage development for the treatment of life-threatening fungal infections in hospitalized patients.

A Versatile Anti-Infective
Treatment of VVC: our lead indication

News

Latest News

SCYNEXIS Presents Data at 2021 ACOG Demonstrating the Positive Outcome and Sustained Response of Investigational Oral Ibrexafungerp (Brexafemme™) in Difficult-to-Treat Patients with Vaginal Yeast Infections

Read More

SCYNEXIS to Present Two Ibrexafungerp (Brexafemmeᵀᴹ) Posters at the 2021 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting

Read More

SCYNEXIS Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

Read More

SCYNEXIS Announces Positive Results from Interim Analyses of Ongoing Phase 3 Studies (FURI and CARES), Demonstrating Oral Ibrexafungerp's Ability to Treat Severe Fungal Infections in the Hospital Setting

Read More

SCYNEXIS to Participate in Maxim Group’s Late Stage Innovations in Women’s Health Virtual Event

Read More

SCYNEXIS and Amplity Health Announce Agreement to Support the Anticipated U.S. Commercialization of BrexafemmeTM (Ibrexafungerp) for Vaginal Yeast Infections

Read More

SCYNEXIS Announces Licensing Agreement and Strategic Partnership with Hansoh Pharma for Rights to Ibrexafungerp in Greater China

Read More

SCYNEXIS Announces Closing of $85 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants

Read More

SCYNEXIS Announces Pricing of $85 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants

Read More
View All News

FAQs

Click here for our list of Frequently Asked Questions

View FAQs
icon

Committed to Helping Patients Overcome and Prevent Difficult-to-Treat Infections

Our team strives to save and improve patients' lives by advancing a novel broad-spectrum antifungal therapy to address difficult-to-treat and often life-threatening infections, and to transforming the anti-infective treatment paradigms for patients worldwide.

More About Us
icon

Our Innovative Antifungal Platform

Our lead candidate, ibrexafungerp (formerly known as SCY-078), is an investigational antifungal agent and the first representative of a novel class of structurally-distinct glucan synthase inhibitors, known as triterpenoids. It is currently under regulatory review for the treatment of vaginal yeast infection, also known as vulvovaginal candidiasis (VVC), and is in late-stage development for multiple indications, including life-threatening fungal infections caused primarily by Candida (including C. auris) and Aspergillus species in hospitalized patients.

Our Science Our Pipeline
icon

Success Backed by Strong Leadership

The innovation that drives our science and pipeline is a direct reflection of our leadership's commitment to bringing ibrexafungerp to patients in need, and ability to advance the product across multiple indications from discovery through to the commercial stage. This leadership has a proven track record and deep antifungal expertise needed to advance ibrexafungerp to commercialization.

Leadership Board of Directors

SCYNEXIS, Inc.

Market/Symbol

Nasdaq: SCYX

Price

Change

52-Week Range

Daily Volume

Day Range

View Detailed Stock Info View Investor Relations View Investor Presentation

Email Alerts

Receive the latest news directly to your inbox

Sign Up